Annual Accounts Receivable
$8.52 M
-$27.94 M-76.64%
December 31, 2024
Summary
- As of March 12, 2025, NTLA annual accounts receivable is $8.52 million, with the most recent change of -$27.94 million (-76.64%) on December 31, 2024.
- During the last 3 years, NTLA annual accounts receivable has risen by +$6.49 million (+319.35%).
- NTLA annual accounts receivable is now -76.64% below its all-time high of $36.46 million, reached on December 31, 2023.
Performance
NTLA Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$8.52 M
-$337.00 K-3.81%
December 31, 2024
Summary
- As of March 12, 2025, NTLA quarterly accounts receivable is $8.52 million, with the most recent change of -$337.00 thousand (-3.81%) on December 31, 2024.
- Over the past year, NTLA quarterly accounts receivable has dropped by -$27.91 million (-76.62%).
- NTLA quarterly accounts receivable is now -76.64% below its all-time high of $36.46 million, reached on December 31, 2023.
Performance
NTLA Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
NTLA Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -76.6% | -76.6% |
| 3 y3 years | +319.4% | +319.4% |
| 5 y5 years | +84.3% | +84.3% |
NTLA Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -76.6% | +319.4% | -76.6% | +372.9% |
| 5 y | 5-year | -76.6% | +319.4% | -76.6% | +793.7% |
| alltime | all time | -76.6% | -100.0% | -76.6% | +793.7% |
Intellia Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $8.52 M(-76.6%) | $8.52 M(-3.8%) |
| Sep 2024 | - | $8.85 M(-28.2%) |
| Jun 2024 | - | $12.33 M(-66.2%) |
| Mar 2024 | - | $36.43 M(-0.1%) |
| Dec 2023 | $36.46 M(+867.5%) | $36.46 M(+461.6%) |
| Sep 2023 | - | $6.49 M(+28.4%) |
| Jun 2023 | - | $5.06 M(+3.1%) |
| Mar 2023 | - | $4.91 M(+30.2%) |
| Dec 2022 | $3.77 M(+85.5%) | $3.77 M(-6.3%) |
| Sep 2022 | - | $4.02 M(+41.0%) |
| Jun 2022 | - | $2.85 M(+58.5%) |
| Mar 2022 | - | $1.80 M(-11.3%) |
| Dec 2021 | $2.03 M(-4.6%) | $2.03 M(-18.5%) |
| Sep 2021 | - | $2.49 M(+25.0%) |
| Jun 2021 | - | $1.99 M(+109.1%) |
| Mar 2021 | - | $953.00 K(-55.3%) |
| Dec 2020 | $2.13 M | $2.13 M(+75.0%) |
| Sep 2020 | - | $1.22 M(-68.5%) |
| Jun 2020 | - | $3.86 M(-71.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | $13.37 M(+189.4%) |
| Dec 2019 | $4.62 M(-38.8%) | $4.62 M(+28.4%) |
| Sep 2019 | - | $3.60 M(-14.1%) |
| Jun 2019 | - | $4.19 M(+16.6%) |
| Mar 2019 | - | $3.59 M(-52.4%) |
| Dec 2018 | $7.55 M(-27.9%) | $7.55 M(+168.3%) |
| Sep 2018 | - | $2.81 M(-67.3%) |
| Jun 2018 | - | $8.61 M(+15.3%) |
| Mar 2018 | - | $7.47 M(-28.7%) |
| Dec 2017 | $10.47 M(+62.2%) | $10.47 M(+133.1%) |
| Sep 2017 | - | $4.49 M(+62.6%) |
| Jun 2017 | - | $2.76 M(+13.1%) |
| Mar 2017 | - | $2.44 M(-62.1%) |
| Dec 2016 | $6.45 M(+545.4%) | $6.45 M(+480.4%) |
| Sep 2016 | - | $1.11 M(+11.2%) |
| Jun 2016 | - | $1.00 M(0.0%) |
| Mar 2016 | - | $1.00 M(0.0%) |
| Dec 2015 | $1.00 M(>+9900.0%) | $1.00 M |
| Dec 2014 | $0.00 | - |
FAQ
- What is Intellia Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Intellia Therapeutics?
- What is Intellia Therapeutics annual accounts receivable year-on-year change?
- What is Intellia Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly accounts receivable year-on-year change?
What is Intellia Therapeutics annual accounts receivable?
The current annual accounts receivable of NTLA is $8.52 M
What is the all time high annual accounts receivable for Intellia Therapeutics?
Intellia Therapeutics all-time high annual accounts receivable is $36.46 M
What is Intellia Therapeutics annual accounts receivable year-on-year change?
Over the past year, NTLA annual accounts receivable has changed by -$27.94 M (-76.64%)
What is Intellia Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of NTLA is $8.52 M
What is the all time high quarterly accounts receivable for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly accounts receivable is $36.46 M
What is Intellia Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, NTLA quarterly accounts receivable has changed by -$27.91 M (-76.62%)